External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

BACKGROUND: The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external validation of the potential biomarkers CLU, ITGB3...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Partheen, Karolina, Levan, Kristina, Österberg, Lovisa, Claesson, Ingela, Sundfeldt, Karin, Horvath, György
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2009
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754489/
https://ncbi.nlm.nih.gov/pubmed/19775429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-336
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires